| Literature DB >> 25884323 |
Ulla Bergfeldt1,2, Tomas Jonsson3,4, Lennart Bergfeldt5, Per Julin6,7.
Abstract
BACKGROUND: Impaired dominant hand function in stroke patients is a common clinical problem. Functional improvement after focal spasticity therapy is well documented but knowledge about central correlates is sparse. Brain activity was therefore followed during therapy with repeated functional magnetic resonance imaging (fMRI). The purpose was to analyse motor function and central nervous system (CNS) correlates in response to a standardized motor task in stroke patients after a comprehensive focal spasticity therapy.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25884323 PMCID: PMC4450484 DOI: 10.1186/s12883-015-0306-4
Source DB: PubMed Journal: BMC Neurol ISSN: 1471-2377 Impact factor: 2.474
Patient characteristics (n = 6) at referral, therapeutic targets, and spasticity therapy
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| F | F | M | F | M | F |
|
| 67 | 55 | 59 | 79 | 75 | 59 |
|
| Cerebral infarction, left, subcortical | Cerebral infarction, left, subcortical | Cerebral infarction, left, subcortical + brain stem infarction | Cerebral infarction, left, subcortical | Cerebral infarction, left, subcortical | Brain stem + cerebellum |
|
| 2.5 | 2 | 2.5 | 3 | 1.5 | 17 |
|
| Hypertension | Hypertension | Hypertension | |||
|
| Baclofen, Felodipin, ASA, Dipyridamol | ASA, Dipyridamol, Lanzoprasol | Baclofen, Fenytoin, Clopidogrel, Pravastatin | ASA, Dipyridamol, Bisoprolol | Baclofen, ASA, Diltiazem, Dipyridamol, Amilorid, Hydroklorthiazid, Acetylcystein, Budesonid, Formoterol | Warfarin |
|
| d4400, d4401, d4403 | d4400-4403 | d4400-4403 | d4401-4403 | d4400-4403 | d4400-4403 |
|
| 2/2/1 = 1.7 | 2/2/2 = 2.0 | 2/3/1 = 2.0 | 1/2/1 = 1.3 | 2/1/1 = 1.3 | 3/3/2 = 2.7 |
|
| 3 | 4 | 4 | 3 | 3 | 4 |
|
| - | - | - | - | - | - |
|
| - | x | - | - | - | - |
|
| - | - | - | - | - | - |
|
| walking stick, walker | - | wheel chair | walking stick, walker, wheel chair | walking stick, walker | walker |
|
| ||||||
|
| fl dig superfic & profundus, fl poll long, flex carpi uln & radialis | fl dig superfic & profundus, fl poll long, flex carpi uln & radialis, brachialis, brachio-radialis | fl dig superfic & profundus, fl poll long, flex carpi uln & radialis, pron teres, biceps, brachialis, pectotalis | fl dig superfic & profundus, fl poll long, flex carpi uln & radialis | fl dig superfic & profundus, fl poll long, flex carpi uln & radialis, pron teres, biceps, brachialis | fl dig superfic & profundus, fl poll long, flex carpi uln & radialis, pron teres, biceps, brachialis, pectoralis |
|
| 120 | 300 | 350 | 130 | 350 | 390 |
|
| x | x | x | x | x | x |
|
| - | x | - | - | - | - |
|
| x | x | x | x | x | - |
Figure 1Automatic definition of 3 Brodmann areas (BA) within the left hemisphere according to the Jülich probability atlas BA4a (blue), BA4p (orange) and BA6 (yellow). These areas are projected on to an averaged brain image from the 10 healthy subjects. Note the overlap, which is due to the inter-individual variability of the extension of these 3 areas.
Functional test results at baseline, and 6 and 12 weeks after therapy initiation
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||
|
| |||||||||
|
| |||||||||
|
|
|
|
|
|
|
|
|
| |
|
| 1.7 | 0.7 | 1.3 | 19 | 23 | 36 | 1.7 | 3.7 | 4.7 |
|
| 2.0 | 0.3 | 1.7 | 5 | 5 | 15 | 1.7 | 5 | 5.3 |
|
| 2.0 | 0.7 | 0.7 | 11 | 18 | 26 | 11.7 | 6 | 7 |
|
| 1.3 | 0.3 | 0.3 | 41 | 41 | 44 | 3 | 3.7 | 4 |
|
| 1.3 | 0.3 | 0.0 | 25 | 27 | 29 | 6.3 | 8 | 5 |
|
| 2.7 | 0.7 | 1.0 | 21 | 14 | 14 | 6 | 0.7 | 1.3 |
|
| 1.85 | 0.5 | 0.85** | 21 | 20.5 | 27.5 | 4.5 | 4.4 | 4.9 |
|
| 1.3-2.7 | 0.3-0.7 | 0-1.7 | 5-41 | 5-41 | 14-44 | 3-11.7 | 0.7-8.0 | 1.3-5.3 |
|
| 1.8 | 0.5 | 0.8** | 20.3 | 21.3 | 27.3* | 5.1 | 4.5 | 4.6 |
*p = 0.05; **p < 0.01, Friedman’s test; significant changes for baseline vs. 6 and 12 weeks according to post hoc analysis with Wilcoxon’s signed rank test.
Changes (%) in mean and maximum BOLD activities in 3 Brodmann areas (BA) during the motor task at session 1 (baseline), 2 (6 weeks), and 3 (12 weeks)
|
| ||||||
|
|
| |||||
|
|
|
|
|
|
|
|
| 1 | 2.90/2.02/1.86 | 3.19/0.96/0.95 | −9/11/10 | 19.5/10.1/18.9 | 22.1/5.52/13.7 | −12/84/37 |
| 2 | 2.31/3.52/3.68 | 2.86/5.58/3.80 | −19/-36/-3 | 10.9/28.4/31.7 | 16.5/33.5/17.2 | −34/-15/85 |
| 3 | 2.24/1.43/3.3 | 2.67/1.36/2.91 | −16/5/13 | 17.8/10.9/19.7 | 19.1/8.20/15.0 | −7/33/31 |
| 4 | 1.20/2.71/2.18 | 1.59/2.50/1.82 | −25/8/20 | 8.79/26.8/15.4 | 13.8/14.9/11.9 | −36/80/30 |
| 5 | 2.76/2.64/2.58 | 1.96/3.38/2.38 | 41/11/8 | 22.4/19.8/17.0 | 18.5/13.7/9.64 | 21/45/76 |
| 6 | 3.62/0.92/0.71 | 4.69/1.05/1.28 | −23/-12/-45 | 33.1/3.52/4.35 | 32.0/7.04/15.1 | 4/-50/-71 |
| Mean | 2.51/2.21/2.39 | 2.83/2.29/2.19 | −8/14/15 | 18.8/16.6/17.8 | 20.3/13.8/13.8 | −11/29/31 |
|
|
|
|
|
|
|
|
| p values | 0.011/0.014 |
| 0.002/0.004 | 0.034/ns |
| 0.003 |
|
| ||||||
|
|
| |||||
|
|
|
|
|
|
|
|
| 1 | 2.37/1.50/1.55 | 2.42/0.76/0.83 | −2/98/87 | 19.5/10.1/18.9 | 22.1/4.53/13.7 | −12/123/37 |
| 2 | 1.14/2.75/2.50 | 1.88/3.44/2.77 | −39/-20/-10 | 8.11/28.4/31.7 | 12.1/22.8/17.2 | −33/25/85 |
| 3 | 1.40/0.98/2.65 | 1.16/0.73/1.44 | 21/34/84 | 10.7/7.89/18.1 | 14.0/5.18/10.8 | −24/52/67 |
| 4 | 0.99/1.41/1.26 | 1.39/1.31/1.30 | −29/8/-3 | 8.79/16.2/6.91 | 13.8/14.0/11.9 | −36/16/-42 |
| 5 | 2.27/2.12/1.45 | 1.59/1.70/2.18 | 43/24/-33 | 18.5/13.9/8.91 | 18.5/1.1/9.22 | 0/15/-3 |
| 6 | 2.96/0.86/0.61 | 2.96/0.70/0.67 | 0/22/-9 | 33.1/2.96/4.35 | 25.6/7.04/5.38 | 29/-58/-19 |
| Mean | 1.86/1.60/1.67 | 1.90/1.44/1.53 | −1/28/19 | 16.4/13.3/14.8 | 17.7/10.9/11.4 | −13/29/21 |
|
|
|
|
|
|
|
|
| p values | 0.045/0.020 |
| 0.003/0.004 | 0.045/ns |
| 0.002/0.008 |
|
| ||||||
|
|
| |||||
| Pt # |
|
|
|
|
|
|
| 1 | 2.81/1.96/1.71 | 3.10/0.94/0.67 | −9/108/155 | 36.4/13.0/18.7 | 34.7/13.0/3.56 | 5/0/430 |
| 2 | 2.59/3.93/3.89 | 2.64/6.15/4.11 | −1/-36/-5 | 10.9/32.8/33.2 | 16.5/39.5/28.3 | −34/-17/17 |
| 3 | 3.08/1.78/3.81 | 2.71/1.50/3.59 | 14/0/619 | 18.3/13.8/22.7 | 19.1/9.60/20.4 | −4/44/11 |
| 4 | 1.51/1.26/2.62 | 1.30/2.28/1.98 | 16/-40/33 | 15.6/26.8/16.7 | 8.50/13.6/11.9 | 84/96/41 |
| 5 | 2.52/3.09/4.72 | 1.53/2.25/3.64 | 65/37/30 | 31.9/24.1/39.0 | 17.7/14.8/25.1 | 80/63/55 |
| 6 | 5.09/1.23/0.88 | 4.10/1.06/1.16 | 24/15/-24 | 27.0/13.9/5.99 | 32.0/10.3/15.1 | −16/35/-60 |
| Mean | 2.93/2.21/2.94 | 2.56/2.37/2.52 | 18/16/32 | 23.3/20.7/22.7 | 21.4/16.8/17.4 | 19/37/82 |
|
|
|
|
|
|
|
|
| p values | 0.003/0.004 |
| 0.015/0.034 | 0.034/0.011 | 0.003 | 0.020/0.015 |
Values from the 10 healthy subjects studied twice serve as reference; p values refer to between-group differences. *p < 0.05 for session 1 vs. 2 in healthy subjects (p < 0.002 applying Bonferroni correction in bold font).
Figure 2Whole brain statistical analysis of the BOLD activity at a group level during the motor task is shown for 10 healthy subjects at the first (a) and the second (b) session. Each figure presents the slices of the brain from the base (upper left) to the top (lower right) with a view from below (R = right) with anterior (front) up and posterior (occiput) down. Significantly (Z > 2.3, p < 0.05) activated voxels are overlaid on mean anatomical image. Activation is seen in primary and secondary motor cortices, supplementary motor cortex, and cerebellum, and three brain slice levels in which these areas are visualized are highlighted within coloured rectangles.
Figure 3The mean BOLD activity is shown before (a) and 12 weeks after (b) intervention in stroke patient #1. Each panel presents the slices of the brain from the base (upper left) to the top (lower right) with a view from below (R = right) with anterior (front) up and posterior (occiput) down. Before therapy the BOLD activity is more pronounced than after, especially in the right hemisphere.